FSPTP (an irreversible inhibitor) is another potent A2AR blocker administered as an intratumoral injection, which reduced the frequency of tumor-infiltrating CD8+ T cells, but not CD4+ T cells or NK cells, in an MB49 bladder cancer model [229]. Here, CD8A is linked to neoplasm.